Development of an International COVID-19 Specific Quality of Life Questionnaire, Phase III. The OSLO COVID-19 QLQ

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

371 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-20

Study Completion Date

2022-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose: to develop an international validated patient-reported outcome measure for COVID-19 patients according to international guidelines.

In this phase III of the project, the preliminary questionnaire of 80 items will be tested. It has been developed based on literature review and interviews with health care professionals and patients (phase I-II).

In Phase III A patients will fill in the questionnaire followed by interviews on relevance, importance and wording of the questionnaire In Phase III B patients will fill in the questionnaire and an debriefing questionnaire. We will do explorative psychometric analyses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital

NCT04345536

COVID-19

COMPLETED

Mechanisms for Covid-19 Disease Complications

NCT04314232

COVID Coronavirus Infection

UNKNOWN

The Corona Study of Middle Norway

NCT05638178

SARS-CoV-2 Acute Respiratory Disease SARS-CoV-2 Sepsis SARS CoV 2 Infection

COMPLETED

Follow-up of Covid-19 Long Term Sequelae

NCT05097677

COVID-19 Pneumonia COVID-19 Respiratory Infection COVID-19 Acute Bronchitis +15 more

COMPLETED

Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19

NCT04505709

Covid19

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project aim to develop an international validated patient-reported outcome measure for COVID-19 patients according to international guidelines. The Phase I and II of this development process have been finalized. Based on a systematic literature review , interviews with 44 health-care professionals and 52 patients in 6-7 countries a final list of 80 questions, the preliminary Oslo COVID-19 QLQ - PW80 ©, is ready to be tested in the current Phase III of the development process.

The objectives of the phase III are:

* In a limited patient group, to check that the items make sense to the target population, that the phrasing and sequence of questions is acceptable, that there are no missing issues and that none of the questions are confusing and/or offensive (Phase IIIA).
* In addition, in a larger patient group, to test hypothesized subscales for psychometric properties including reliability, prevalence and variance (e.g. Cronbach's alpha coefficient and correlation-based methods) (Phase IIIB).

The end-product, the international COVID-19- specific questionnaire, will be a psychometrically robust patient-reported outcome measure (PROM) to assess HRQoL in patients with or after COVID-19 disease

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19, Patient Reported Outcome Measures, Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention. Method study. Psychometric testing

Patients will fill in the questionnaire followed by an interview (phase IIIA) or a debriefing questionnaire (Phase IIIB)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with verified SARS-CoV-2 infection (positive test according to local/national standards)
* Patients with active or previous symptomatic COVID-19 disease
* In-patients in hospitals and nursing homes or out-patients in hospitals or patients discharged from institutions to their home/covid-19 centres or patients staying at home/covid-19 centres during the course of the disease
* Patients aged 18 years and older
* Ability to read and comprehend the process and study documents as judged by the investigator
* Written informed consent

Exclusion Criteria

* Patients in intensive care units (can be recruited after they have been dismissed)
* Inability to read and comprehend the process and study documents as judged by the investigator

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No